Literature DB >> 17199783

Evaluation of renal tubular function in children taking anti-epileptic treatment.

Bulent Unay1, Ridvan Akin, S Umit Sarici, Faysal Gok, Ismail Kurt, Erdal Gokcay.   

Abstract

AIM: To assess the effects of anti-epileptic drugs on renal tubular function.
METHODS: Urinary N-acetyl-beta-D-glucosaminidase activity was measured in 114 epileptic children (mean age 5.6 +/- 1.1 years) who were undergoing monotherapy with valproate (n = 46), carbamazepine (n = 34), lamotrigine (n = 13) and combined therapy with valproate+carbamazepine (n = 21).
RESULTS: The urinary N-acetyl-beta-D-glucosaminidase index of valproate (P < 0.01), carbamazepine (P < 0.05) and polytherapy group (P < 0.01) were significantly elevated when compared with that of the control group. No significant difference in N-acetyl-beta-D-glucosaminidase levels was found between the lamotrigine group and the control subjects. We found that the distribution of the N-acetyl-beta-D-glucosaminidase values of patients depended significantly on the length of therapy (P < 0.01). The level of urinary excretion of N-acetyl-beta-D-glucosaminidase was significantly higher in the patients who were taking long-term treatment (>10 years) with valproate, carbamazepine and combined therapy than those taking therapy shorter than 10 years (P < 0.01). The mean serum concentrations of valproate and carbamazepine were 68.7 +/- 17.44 microg/mL and 5.41 +/- 1.23 microg/mL, respectively. There was a significant correlation between the serum concentration of valproate and urinary N-acetyl-beta-D-glucosaminidase levels (r = 0.44, P < 0.01). There was also a significant correlation between the serum concentration of carbamazepine and N-acetyl-beta-D-glucosaminidase excretion (r = 0.52, P < 0.01).
CONCLUSION: The present study demonstrated that in patients treated with valproate and carbamazepine, an impairment of tubular function can be present, whereas lamotrigine does not cause any significant change.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17199783     DOI: 10.1111/j.1440-1797.2006.00699.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  5 in total

Review 1.  Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.

Authors:  Gail D Anderson; Shahin Hakimian
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

Review 2.  The effects of sodium valproate on the renal function of children with epilepsy.

Authors:  Mark Jonathan Knights; Eric Finlay
Journal:  Pediatr Nephrol       Date:  2013-05-30       Impact factor: 3.714

3.  Outcome measures in pediatric polypharmacy research: a scoping review.

Authors:  Negar Golchin; Hannah Johnson; Paul M Bakaki; Neal Dawson; Elia M Pestana Knight; Sharon B Meropol; Rujia Liu; James A Feinstein; Shari D Bolen; Lawrence C Kleinman; Alexis Horace
Journal:  Drugs Ther Perspect       Date:  2019-07-12

4.  Renal tubular dysfunction measured by N-acetyl-beta glucosaminidase/Creatinine activity index in children receiving antiepileptic drugs: a randomized controlled trial.

Authors:  Mojgan Mazaheri; Afshin Samaie; Vahid Semnani
Journal:  Ital J Pediatr       Date:  2011-05-14       Impact factor: 2.638

5.  Effects of valproic acid on organic acid metabolism in children: a metabolic profiling study.

Authors:  K E Price; R E Pearce; U C Garg; B A Heese; L D Smith; J E Sullivan; M J Kennedy; J F Bale; R M Ward; T K H Chang; F S Abbott; J S Leeder
Journal:  Clin Pharmacol Ther       Date:  2011-05-04       Impact factor: 6.875

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.